Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal International Journal of Public Health Science (IJPHS)
Krishnamoorthy, HemaNandini Rajendran
Unknown Affiliation
Health Professions

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Genome mining of secondary metabolites from marine Streptomyces spp. as potent therapeutics for RET-specific non small-cell lung cancer Gurmuras, Rhydhy Rasika; Krishnamoorthy, HemaNandini Rajendran; Karuppasamy, Ramanathan
International Journal of Public Health Science (IJPHS) Vol 14, No 3: September 2025
Publisher : Intelektual Pustaka Media Utama

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11591/ijphs.v14i3.26208

Abstract

The rearranged during transfection (RET) gene encodes a tyrosine kinase oncogene implicated in various cancers, including non-small-cell lung cancer (NSCLC). Till now, multiple kinase inhibitors are commonly used to treat RET-positive NSCLC. However, these inhibitors often exhibit significant toxicity and demonstrate reduced efficacy and specificity toward RET. Recently, bioactive compounds derived from marine sources have shown promising anticancer properties. Therefore, this study aimed to identify effective bioactive compounds from marine Streptomyces species using a virtual screening approach to address these limitations. A literature search identified 20 marine Streptomyces species as potential sources of bioactive compounds. The antibiotics and secondary metabolite analysis shell (antiSMASH) online tool were used to analyze the gene clusters of these marine Streptomyces species, revealing 7,251 metabolites. A total of 661 distinct metabolites were analyzed through a comprehensive array of virtual screening methodologies. The molecular docking and pharmacokinetic analysis resulted in the identification of four metabolites with better binding scores and pharmacological properties than pralsetinib. Collectively, we hypothesize that the identified bioactive compounds could be considered as potent leads for further analysis.
Co-Authors Gurmuras, Rhydhy Rasika Karuppasamy, Ramanathan